- Home
- APLS
as 01-21-2025 4:00pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 4.0B | IPO Year: | 2017 |
| Target Price: | $46.71 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $24.34 - $71.90 | Next Earning Date: | 02-25-2025 |
| Revenue: | $715,216,000 | Revenue Growth: | 162.10% |
| Revenue Growth (this year): | 95.82% | Revenue Growth (next year): | 12.02% |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Deschatelets Pascal | APLS | Chief Scientific Officer | Jan 13 '25 | Sell | $28.70 | 2,288 | $65,670.40 | 1,138,195 | |
| Nicholson Nur | APLS | Chief Technical Officer | Jan 13 '25 | Sell | $28.70 | 2,632 | $75,543.93 | 54,156 | |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Jan 13 '25 | Sell | $28.70 | 2,170 | $62,283.56 | 88,100 | |
| Townsend Adam J. | APLS | Chief Commercial Officer | Jan 13 '25 | Sell | $28.70 | 2,685 | $77,065.14 | 90,269 | |
| Lewis Karen | APLS | Chief People Officer | Jan 13 '25 | Sell | $28.70 | 1,599 | $45,894.66 | 45,099 | |
| Francois Cedric | APLS | Chief Executive Officer | Jan 13 '25 | Sell | $28.70 | 6,247 | $179,302.02 | 307,415 | |
| Eisele Jeffrey | APLS | Chief Development Officer | Jan 13 '25 | Sell | $28.70 | 264 | $7,577.35 | 56,881 | |
| Chopas James George | APLS | VP/Chief Accounting Officer | Jan 13 '25 | Sell | $28.70 | 783 | $22,473.74 | 37,358 | |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Jan 13 '25 | Sell | $28.70 | 1,599 | $45,894.66 | 58,796 | |
| Eisele Jeffrey | APLS | Chief Development Officer | Dec 23 '24 | Sell | $33.09 | 63 | $2,084.67 | 56,881 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Apellis Shares Rise After Reporting Preliminary Q4, Full-Year Product Sales Results
GlobeNewswire
9 days ago
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
12 days ago
Apellis Announces Keli Walbert to Join the Board of Directors
GlobeNewswire
15 days ago
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
15 days ago
RBC Raises Price Target on Apellis Pharmaceuticals to $26 From $24, Keeps Sector Perform Rating
GlobeNewswire
16 days ago
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Simply Wall St.
19 days ago
Exploring 3 High Growth Tech Stocks In The United States
MT Newswires
a month ago
Goldman Sachs Downgrades Apellis Pharmaceuticals to Neutral From Buy, $36 Price Target
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.